ArQule Strengthens Executive Team with Two Key Appointments

By: ArQule, Inc. via Business Wire News Releases

May 24, 2018 at 07:00 AM EDT

ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning.

“We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci. “Marc’s medical background, paired with his experience in healthcare and investment banking, and Shirish’s expertise in both drug development and operations will be essential as ArQule continues to advance its precision medicine programs in both oncology and rare diseases.”

Dr. Schegerin joins ArQule with extensive experience in the pharmaceutical industry and healthcare investment banking. Prior to ArQule, Dr. Schegerin was a Healthcare Investment Banking Director at Citigroup. His prior experience includes Strategy and Development leadership roles at Sage Therapeutics and Biogen, and he began his career at Goldman Sachs. Dr. Schegerin received an M.D. from Dartmouth Medical School and an M.B.A. from the Tuck School of Business at Dartmouth.

Dr. Schegerin stated “It is an exceptional opportunity to join the team at ArQule. I look forward to working with the rest of the executive team to advance ArQule’s corporate strategy to deliver significant value for patients and shareholders.”

Until recently, Dr. Hirani was at ARIAD Pharmaceuticals as vice president, drug development. Prior roles at ARIAD include vice president of program and alliance management and vice president of development operations & planning. Dr. Hirani had executive program management and product development roles at other life science companies including Transkaryotic Therapies, Dyax, ImmuLogic and Genzyme. Dr. Hirani received a B.S. and Ph.D. from Queen Elizabeth College, University of London.

Dr. Hirani said “I am pleased to join ArQule at such an exciting time. I believe ArQule’s pipeline of clinical programs has great potential, and I look forward to further developing its biomarker defined oncology and rare disease programs.”

About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), and in Phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.